Otic neural progenitors
PreclinicalSmall molecule
Otic neural progenitors is one of 8 small molecule programs targeting Sensorineural Hearing Loss. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Sensorineural Hearing Loss
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Trexall
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Stem Cell Dip
TTruway Health, Inc.
Phase 1
Otic neural progenitors
RRinri Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Otic neural progenitors. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRinri Therapeutics